Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 325 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagus Adenocarcinoma Clear all
Completed Phase 2 Interventional Results available

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

NCT00891878
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions
capecitabine, sunitinib malate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
182
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

NCT02830594
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
Radiation · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 28, 2026, 5:18 PM EDT
Recruiting Phase 2 Interventional

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

NCT04682158
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00096031
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
152
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 28, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

NCT00006472
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Up to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 28, 2026, 5:18 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus

NCT00005607
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
Robert H. Lurie Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

NCT00985192
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
everolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 28, 2026, 5:18 PM EDT
Not listed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

NCT00005876
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 28, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

NCT00447226
View directory record Official record
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 28, 2026, 5:18 PM EDT
Not yet recruiting Phase 1 Interventional

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT07594548
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Futibatinib, Magnetic Resonance Imaging, Paclitaxel, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

NCT02872116
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 28, 2026, 5:18 PM EDT
Not yet recruiting No phase listed Observational

A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

NCT07517211
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

NCT02638909
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
ceritinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 28, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

NCT05524844
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Sample Collection, Endoscopy results, Dietary questionnaire
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 28, 2026, 5:18 PM EDT
Completed No phase listed Observational

Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management

NCT02075905
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Adenocarcinoma, Intestinal Metaplasia, Dysplasia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 28, 2026, 5:18 PM EDT
Completed No phase listed Observational

The Microenvironment in Barrett's Esophagus

NCT03060642
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Tethered capsule sponge, Electronic nose device
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00316862
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, irinotecan hydrochloride, therapeutic conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Elkhart, Indiana • Kokomo, Indiana • La Porte, Indiana + 18 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 28, 2026, 5:18 PM EDT
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
View directory record Official record
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

NCT00165490
View directory record Official record
Conditions
Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Interventions
Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery
Drug · Device · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 28, 2026, 5:18 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04097028
View directory record Official record
Conditions
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Trifluridine and Tipiracil Hydrochloride, Oxaliplatin
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Buffalo, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

NCT00496860
View directory record Official record
Conditions
Progressive Metastatic Malignancies
Interventions
ALT-801
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 28, 2026, 5:18 PM EDT
Completed Phase 1 Interventional

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

NCT01236443
View directory record Official record
Conditions
Barrett's Esophagus, CIS, High Grade Dysplasia
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 28, 2026, 5:18 PM EDT